Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 10Gastrointestinal 7Breast 5Other hematologic neoplasm 4CNS 4Dermatologic 3Tumor-Agnostic 2Sarcoma 2Plasma cell 2Other solid neoplasm 2Gynecologic 2Thoracic 1Head & Neck 1Genitourinary 1

Conditions

Melanoma 3Neoplasm Metastasis 2Skin Neoplasms 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 339Nivolumab 305Ipilimumab 274Cyclophosphamide 195aldesleukin 148Interleukin-2 110fludarabine phosphate 107trametinib 85Temozolomide 83fludarabine 81Dacarbazine 81dabrafenib 77Radiotherapy 75Biopsy 75Vemurafenib 71Imiquimod 53Bevacizumab 51sargramostim 50Magnetic Resonance Spectroscopy 50Specimen Handling 49Radiosurgery 49Peripheral Blood Stem Cell Transplantation 49Paclitaxel 49Aminolevulinic Acid 49binimetinib 48Carboplatin 48Blood Specimen Collection 47cemiplimab 46Cisplatin 453-ingenyl angelate 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Antibodies, Monoclonal × Dermatologic × Clear all
NCT01335009 2021-09-01

Efficacy Study of Pharmacokinetic(PK)/Pharmacodynamic(PD) Relationship of Monotherapy MORAb-004 in Metastatic Melanoma

Eisai Inc.

Phase 2 Completed
76 enrolled 13 charts
Dermatologic

Melanoma, Neoplasm Metastasis

NCT00356460 2014-03-19

Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma

Sanofi

Phase 1 Completed
29 enrolled
DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma

NCT00094653 2011-07-11

MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma

Bristol-Myers Squibb

Phase 3 Completed
1,783 enrolled 29 charts
Dermatologic

Melanoma, Neoplasm Metastasis, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡